Literature DB >> 16195798

New delivery approaches for pediatric brain tumors.

Ian F Pollack1, Robert Keating.   

Abstract

For many types of childhood brain tumors, including malignant gliomas, disease progression at the primary site is the predominant mode of treatment failure. Accordingly, interest has been directed during the last decade on exploring strategies to enhance the delivery of therapeutically active agents into the tumor microenvironment. Two approaches that have been the focus of considerable attention in the treatment of adult malignant brain tumors include interstitial administration of chemotherapeutic agents using time-release polymers and convection-enhanced delivery of immunotoxin conjugates targeted to receptors overexpressed in brain tumors relative to normal brain cells. Although it remains to be determined whether these approaches will lead to meaningful improvements in disease control and long-term prognosis in children with brain tumors, the encouraging results from studies in adults support the rationale for further exploring these strategies in the pediatric setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195798     DOI: 10.1007/s11060-005-6763-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  121 in total

Review 1.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery.

Authors:  D R Groothuis
Journal:  Neuro Oncol       Date:  2000-01       Impact factor: 12.300

2.  Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma.

Authors:  Juergen Voges; Regina Reszka; Axel Gossmann; Claus Dittmar; Raphaela Richter; Guido Garlip; Lutz Kracht; Heinz H Coenen; Volker Sturm; Karl Wienhard; Wolf-Dieter Heiss; Andreas H Jacobs
Journal:  Ann Neurol       Date:  2003-10       Impact factor: 10.422

3.  Treatment of craniopharyngiomas--the stereotactic approach in a ten to twenty-three years' perspective. I. Surgical, radiological and ophthalmological aspects.

Authors:  E O Backlund; B Axelsson; C G Bergstrand; A L Eriksson; G Norén; E Ribbesjö; T Rähn; P O Schnell; L Tallstedt; M Sääf
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.

Authors:  R W Rand; R J Kreitman; N Patronas; F Varricchio; I Pastan; R K Puri
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

5.  The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.

Authors:  S A Dahlborg; A Petrillo; J R Crossen; S Roman-Goldstein; N D Doolittle; K H Fuller; E A Neuwelt
Journal:  Cancer J Sci Am       Date:  1998 Mar-Apr

6.  Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945.

Authors:  J H Wisoff; J M Boyett; M S Berger; C Brant; H Li; A J Yates; P McGuire-Cullen; P A Turski; L N Sutton; J C Allen; R J Packer; J L Finlay
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

7.  Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.

Authors:  D W Laske; O Ilercil; A Akbasak; R J Youle; E H Oldfield
Journal:  J Neurosurg       Date:  1994-03       Impact factor: 5.115

Review 8.  Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas.

Authors:  Michael Weaver; Douglas W Laske
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

9.  Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas.

Authors:  K Kohshi; Y Kinoshita; H Imada; N Kunugita; H Abe; H Terashima; N Tokui; S Uemura
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 10.  Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas.

Authors:  Amish C Shah; Dale Benos; G Yancey Gillespie; James M Markert
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.506

View more
  1 in total

Review 1.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.